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Abstract
Heart failure is a chronic disease responsible for over 11 million outpatient clinic
visits each year. According to the Healthcare Cost and Utilization Project (2009), heart
failure is one of the most frequent principal diagnoses utilized. Hypokalemia and
hyperkalemia, which can be caused by some of the medications used to treat heart failure,
are often associated with cardiac arrhythmias and sudden cardiac death. The researchers
investigated healthcare provider compliance with the recommended 2009 American
College of Cardiology Foundation/American Heart Association guidelines for monitoring
routine serum potassium levels in heart failure patients. Sister Callista Roy's Adaptation
Model was used as the conceptual framework to guide this study's assessment of
healthcare providers' monitoring levels of serum potassium, our main intracellular
electrolyte. Using a retrospective chart review, 200 charts from two rural primary care
clinics in north and east central Mississippi were examined regarding the follow-up
monitoring of potassium levels in heart failure patients. Participants were 18 years of age
and older.
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CHAPTER I
Dimensions of the Problem
Background
Heart failure is a condition resulting in the loss or dysfunction of heart muscle. It
is characterized by venous congestion, inadequate peripheral oxygen delivery, and
ventricular dilation/hypertrophy which lead to circulatory abnormalities. This disease
can occur as the result of impaired pumping of blood out of the heart, called systolic
heart failure, or impaired relaxation of heart muscle, called diastolic heart failure. In
some patients, abnormalities of both systolic and diastolic heart dysfunction can
co-exist.
Certain medications used in the treatment of heart failure, such as diuretics,
angiotensin-converting enzyme inhibitors (ACE-I), angiotensin II receptor blockers
(ARB), beta-blockers, and aldosterone antagonists, can have adverse effects on the
body's potassium level. Fluid and electrolyte disorders accounted for 17% of the
secondary diagnoses for heart failure in 2009, which was an increase from 11% in 1997
(Wier et ah, 2011). An appropriate potassium level is needed to maintain the body's fluid
balance, conduct nerve impulses and muscle contraction, and help prevent cardiac
arrhythmias. Patients with heart failure should maintain a potassium level in the
4.0-5.0 mEq/L range (Jessup et ah, 2009). An alteration of the potassium level,
either hyperkalemia or hypokalemia, can affect a patient's cardiac conduction and
excitability which can lead to sudden cardiac injury or death (Hunt et al., 2005).
Hypokalemia, which is common in heart failure, can enhance cell membrane excitability
and delay ventricular repolarization. Hyperkalemia, another common complication of

1

2
heart failure, can affect the repolarization phase of the heart and depress the contraction
of the sinoatrial node. Both of these conditions predispose patients to cardiac
arrhythmias, therefore increasing their mortality rate (Bowling et ah, 2009).
Heart failure affects males and females, all age groups from children to the
elderly, and all races. At 40 years of age, the lifetime risk for developing heart failure for
both men and women is 1 in 5. At 80 years of age, the remaining lifetime risk for
developing a new diagnosis of heart failure remains at 20%, despite the fact that the
patient has a much shorter life expectancy (Roger et al., 2011). The incidence of heart
failure increases with age. Statistical data demonstrates a fourfold increase in new
diagnosis for Caucasian men greater than 85 years (Roger et ah, 2011).
An estimated 6 million people in the U.S. have been diagnosed with heart failure,
with over 670,000 new cases being diagnosed each year (Centers for Disease Control and
Prevention [CDC], 2012). Nearly 1.4 million people 60 years of age and under have been
diagnosed with heart failure, and African-Americans are 1.5 times more likely to develop
this disease than Caucasians (Emory Healthcare Heart and Vascular, 2012). According to
the Healthcare Cost and Utilization Project of 2009 (Wier et al., 2011), heart failure was
listed among the top 10 most frequent principal diagnoses utilized. Heart failure can be
contributed to approximately 287,000 deaths per year (Emory Healthcare Heart and
Vascular, 2012). The Heart Failure Society of America (n.d.) reported that < 50% of
patients will survive 5 years after the initial diagnosis of heart failure, with < 25% of
patients surviving after 10 years of initial diagnosis. Sudden death is common in patients
with heart failure, occurring at a rate of 6 to 9 times greater than the general population
(Emory Healthcare Heart and Vascular, 2012). The diagnosis of heart failure is
mentioned on 1 out of 9 death certificates in the U.S. (Roger et al., 2011). The poor
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prognosis can be linked to a limited understanding of the disease process, prevalence of
comorbid conditions, and socioeconomic status.
Heart failure is responsible for 11 million outpatient clinic visits each year, and
for more hospitalizations than all forms of cancer combined (Emory Healthcare Heart and
Vascular, 2012). Heart failure accounts for nearly 875,000 hospitalizations and is the
most common diagnosis documented in hospitalized patients 65 years of age and older
(Emory Healthcare Heart and Vascular, 2012). The Prevention Quality Indicator for
Heart Failure hospital readmission rates for 2009 indicated the highest rate is for 75 years
of age and older, with approximately 2,500 per 100,000 people (U.S. Department of
Health and Human Services Agency for Healthcare Research and Quality [AHRQ],
2012). Groups of patients 65 to 74 years of age had a rate of approximately 840 out of
100,000 people, 40 to 64 years of age had a rate of approximately 200 out of 100,000
people, and 18 to 39 years of age had a rate of approximately 19 out of 100,000 people
(AHRQ, 2012).
The economic burden of managing heart failure in the U.S. can be overwhelming.
Heart failure is a serious public health concern with a cost of approximately $40 billion
from health services and medications, as well as the loss of productivity (CDC, 2012).
An estimated $2.6 trillion was spent on health care in 2009, which represented more than
17.6% of the gross domestic product for the U.S.; moreover heart failure expended more
Medicare dollars than any other diagnosis (Dunlay et ah, 2010). The increased
prevalence of heart failure can be illustrated by frequent hospitalizations, a growing
mortality rate, a complex treatment regimen, and a rising financial and societal burden.
Compliance with the 2009 American College of Cardiology Foundation/American
Heart Association (ACCF/AHA) guidelines (see Appendix A) for monitoring routine
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potassium levels with the management of heart failure could potentially decrease adverse
cardiac outcomes (Jessup et ah, 2009). The Institutes for Clinical Systems Improvement
(ICS!) Guidelines for Heart Failure in Adults (2011) (see Appendix B) further
recommend that stable patients in the clinic setting should have electrolyte levels
monitored at least every 4 months for the duration of the heart failure medication therapy.
If an electrolyte imbalance is discovered, increased lab monitoring would be justified
until levels return to normal. According to the AHRQ, patients may require
hospitalization if their condition is not effectively monitored in the outpatient setting
(2012).

Problem Statement
Despite many medical advances, the incidence of heart failure continues to rise.
Heart failure adds to the economic burden in our country and greatly increases a patient's
mortality rate. Certain medications used in the treatment of heart failure can have
adverse effects on serum potassium levels. Because the lack of testing serum potassium
levels can lead to life-threatening cardiac complications, it is important to ensure that the
healthcare provider is monitoring serum potassium levels routinely in patients with a
diagnosis of heart failure.

Statement of Purpose
The purpose of this study was to evaluate healthcare providers' compliance with
the recommended 2009 ACCF/AHA guidelines for monitoring routine serum potassium
levels in heart failure patients. The researchers of this study focused on the importance of
monitoring routine serum potassium levels in heart failure patients at least every 4
months. The results of this study could help healthcare providers effectively manage
heart failure patients and possibly help prevent the development of life-threatening
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complications. According to the guidelines and latest evidence-based practice, the
healthcare provider should routinely monitor serum potassium levels. Devastating
outcomes such as cardiac arrest can be the result of severe hypokalemia.

Significance of the Study
Heart failure is widely recognized as an increasingly common health problem
associated with a high mortality rate. It can result from any condition that interferes with
blood volume being sufficiently pumped from the heart. Potassium, the main
intracellular electrolyte, plays a critical role in the heart's electrical conduction. Serum
potassium levels affect cardiac automaticity and membrane excitability as well as
repolarization (Bowling et ah, 2009).
Many of the medications used in the treatment of heart failure can alter the body's
potassium level. Other factors such as renal function can also affect potassium levels.
Patients with heart failure should maintain a potassium level in the 4.0-5.0 mEq/L range
(Jessup et ah, 2009).
Efforts should be made by healthcare providers to routinely monitor for changes
in serum potassium levels in order to help prevent potentially life-threatening cardiac
arrhythmias. Data from the current research can be applied to show the importance of
following the recommended 2009 ACCF/AHA guidelines for monitoring serum
potassium levels in the treatment of heart failure. Following evidence-based guidelines
has been considered to have substantial medical advantages. The healthcare provider will
utilize these heart failure guidelines in the detection, prevention, and management of this
condition. Critical evidence indicates that both hypokalemia and hyperkalemia may
cause fatal arrhythmias.
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The study by the current researchers provides data regarding compliance with the
2009 ACCF/AHA guidelines, differences in treatment as evidenced by payer source, as
well as age, sex, and ethnicity of participants. There is limited current information in this
area of study.
Theoretical Foundation
Sister Callista Roy's Adaptation Model (RAM) will be used to guide this research
study. This theory provides the framework that will assist in evaluating the role of the
healthcare provider related to caring for a patient's physical, medical, social, and
enviromnental issues associated with adapting to a chronic illness, such as heart failure.
By utilizing this theory, the healthcare provider/patient relationship can be used to
achieve a comprehensive approach to efficient and effective healthcare management.
The RAM nursing theory views the individual as a holistic adaptive system as
related to the concepts of person, health, environment, and nursing (George, 2011). It is
aimed at understanding human behavior in order to maintain and enhance coping
mechanisms to promote optimal health. The individual must have the ability to adapt to
biological and psychological changes.
Adaptation includes two control processes, the regulator and the cognator
subsystem coping mechanisms (George, 2011). The regulator subsystem includes
automatic reflexes through endocrine, neural, and chemical channels. The cognator
subsystem processes are associated with perception and information processing, learning,
judgment and emotion. The effects of the regulator and cognator processes interrelate
and are measured by behavioral outcomes. Adaptation occurs when these subsystems are
stimulated, causing a change in behavior measured in physiologic and psychosocial
modes.
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Adaptation can be grouped into four modes: physiological-physical, selfconcept/group identity, role function, and interdependence (George, 2011). The
physiological mode represents the physical body and environmental interactions. It
includes basic human needs such as oxygenation, nutrition and fluid balance, elimination
patterns, activity and rest, and protection. The self-concept mode represents the
maintenance of the psyche and spirit. It represents an individual's perceptions or beliefs,
which are central to behavior responses. The role function mode represents social
integrity. It represents an individual or group's adaptation to role changes. The
interdependence mode also represents social integrity. It includes the personal
relationships and the need for love, respect, and security.
The individual is also continuously influenced by different types of internal and
external stimuli (George, 2011). Focal stimulus is the most demanding situation and is
perceived as an immediate concern. Contextual stimulus is an internal or external factor
that will produce a positive or negative response. Residual stimulus is a factor, such as
an attitude or habit, which can produce an uncertain effect. Observation of an
individual's behavior can identify the effectiveness of his or her coping abilities. Coping
mechanisms are viewed as either adaptive or ineffective. A provider should work with
the patient in order to develop intervention goals needed to meet positive adaptive coping
strategies. Monitoring serum potassium levels at least every 4 months and adjusting the
medication regimen if the serum potassium level is not in the recommended range help
the patient adapt to the effects of heart failure. Adaptive mechanisms are appropriate
responses for strengthening positive actions. Ineffective mechanisms will prevent the
individual's ability for effective change and promotion of health.
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Research Questions
Research questions were constructed to guide this investigation and assist in
obtaining data. The study's objectives were to analyze the healthcare providers'
documentation of routine monitoring of potassium levels in heart failure patients. The
following questions were addressed:
1. Was the serum potassium level in patients being treated for heart failure
monitored and documented at least every 4 months as recommended by the
ICSI Guidelines for Heart Failure in Adults?
2. Was the potassium level in the recommended range of 4.0-5.0 mEq/L
according to the 2009 ACCF/AHA recommended guideline when monitored?
3. If the potassium level was not in the recommended range, was there a
medication adjustment?
Definition of Terms
For the purposes of this study, the following terms were defined:
Serum potassium
Theoretical: A chemical element that serves as both the principal cation in
intracellular fluid and an important electrolyte in extracellular fluid. It has many
functions, including metabolism, cell membrane homeostasis, nerve conduction,
and muscle contraction (Venes, 2001).
Operational: Serum potassium lab values of heart failure patients
obtained through retrospective chart reviews.
Patient
Theoretical: One who is sick with, or being treated for, an illness or injury; an
individual receiving medical care (Yenes, 2001).
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Operational: Person who has sought medical care at the primary care clinic on
prior occasions before the retrospective review of their chart.
Heart Failure
Theoretical: The heart's inability to circulate blood effectively enough to meet
the body's metabolic needs. Heart failure may affect the left ventricle, right ventricle, or
both. It can result from the impaired ejection of blood from the heart during systole or
from impaired relaxation of the heart during diastole (Venes, 2001).
Operational: a condition that results in the loss of heart muscle leading
to circulatory abnormalities. Patients with ICD-9 diagnosis code 428.
ICSI Guidelines for Heart Failure
Theoretical: Evidence-based healthcare guidelines developed by an independent,
nonprofit healthcare improvement organization that unites clinicians, health plans,
employers, policymakers, and consumers to improve health, optimize the patient
experience, and make health care more affordable (Institute for Clinical Systems
Improvement, 2011).
Operational: Evidence-based guideline for heart failure in adults used by the
current researchers as the recommended timeframe that serum potassium should be
monitored.
Recommended range
Theoretical: The difference between the highest and lowest in a set of variables
or in a series of values or observations (Venes, 2001).
Operational: The difference between the lowest mEq/L of potassium (4.0
mEq/L) and the highest mEq/L of potassium (5.0 mEq/L) a person with heart failure
should have as stated by the ACCF/AHA (Jessup et ah, 2009).
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ACCF/AHA guidelines
Theoretical: Evidence-based health care guidelines developed by a group of
medical professionals that have jointly engaged in critically evaluating the use of
diagnostic procedures and therapies as they are introduced to effectively manage or
prevent cardiovascular disease since 1980 (Jessup et ah, 2009).
Operational: Evidence-based guidelines for the diagnosis and management of
heart failure in adults, used by the current researchers as a guide for the recommended
range of potassium as well as a medication regimen for patients diagnosed with heart
failure, ICD-9 diagnosis code 428.
Medication adjustment
Theoretical: A medication change made to improve function or condition (Venes,
2001).
Operational: An increase or decrease of dosage or amount made in a patient's
medication regimen, i.e. ace inhibitor, angiotensin receptor blocker, diuretic, or
aldosterone antagonist that would be made due to a serum potassium level out of the
recommended range.
Hypokalemia
Theoretical: An abnormally low concentration of potassium in the
blood (Venes, 2001).
Operational: A serum potassium lab value of heart failure patients
< 4.0 mEq/L.
Hyperkalemia
Theoretical: An excessive amount of potassium in the blood (Venes,
2001).
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Operational: A serum potassium lab value of heart failure patients
>5.0 mEq/L.
Assumptions
Clinical practice guidelines exist to help healthcare providers effectively manage
heart failure. For the purpose of this study, the following assumptions were made:
1. Healthcare providers are knowledgeable regarding the 2009 ACCF/AHA
guidelines for monitoring serum potassium levels in the treatment of heart
failure.
2. Information concerning the serum potassium level, medications, age, gender,
ethnicity and payer source is documented on the patient's charts.
3. Documentation regarding heart failure diagnosis and treatments are sufficient
for data collection.
Limitations
The limitations noted for this research study were as follows.
1. The sample was limited to charts of adult patients, 18 years of age and older,
being treated with a diagnosis of heart failure.
2. Participants were selected from two rural primary care clinics in north and
east central Mississippi, which limited the generalizability to a smaller
geographic area.
3. The provider's adherence to the guidelines relied on their documentation in
the medical records from these two rural primary care clinics.
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Summary
Despite advances in pharmacological treatment, the prevalence of heart failure is
on the rise. Inpatient and outpatient management of this condition exhausts more
Medicare monies than any other diagnosis (Dunlay et al, 2010). An alteration in
potassium levels, either hyperkalemia or hypokalemia, can greatly impact a heart failure
patient's morbidity and mortality. The increased incidence of heart failure, in addition to
complications caused by an alteration of potassium, supported the need for careful
evaluation of these patients. The purpose of this study was to determine if healthcare
providers are monitoring serum potassium levels in heart failure patients according to the
2009 ACCF/AHA guidelines. Proper assessment, diagnosis, and treatment are needed to
provide quality care to the heart failure patient.

CHAPTER II
Review of Literature
Each year in the United States, more than 670,000 people are diagnosed with
heart failure. A plethora of existing comorbidities, such as diabetes, hypertension, and
hyperlipidemia, contribute to heart failure. Socioeconomic status, race, and culture of the
population can be linked with progression of this deadly disease. The following review
of literature supports the significance of appropriate treatment of heart failure.
In a quantitative, non-randomized propensity-matched study conducted by Alper
et al. (2009) data were collected from participants in a randomized trial in the early
1990s. The researchers sought to determine the long-term effects of low serum
potassium on mortality and hospitalization of older adults age 65 years and over
diagnosed with chronic systolic and diastolic heart failure. The elderly are often
excluded from clinical trials; therefore, existing data are limited in the > 65-year-old age
group.
The large randomized clinical trial was conducted during 1991-1993 in 186 U.S.
and 116 Canadian locations. From the sample of 7,788 participants in the Digoxin
Investigative Group (DIG) trial, 4,036 were 65 years of age or older. A total of 3,598 out
of 4,036 had data on baseline serum potassium levels (Alper et al., 2009). After
exclusion of participants with serum potassium > 5.0mEq/L, a subset of 3,274 individuals
were identified. A total of 590 of the 3,274 participants had low potassium defined as
serum potassium < 4.0 mEq/L, and 2,684 participants had normal potassium defined as
4.0-4.9 mEq/L. Propensity score matching was used to balance the covariates between
patients with low versus normal potassium. The researchers used a non-parsimonious
multivariable logistic regression model to estimate propensity scores (Alper et al., 2009).
13
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Propensity scoring tor hypokalemia was defined as the conditional probability of that
participant developing hypokalemia given his or her baseline covariates (Alper et ah,
2009). After matching, 1,670 participants had normal serum potassium levels of 4.0-4.9
mEq/L, and 561 or 95% of the initial 590 had low serum potassium documented < 4.0
mEq/L.
For matching purposes with this model, the dependent variable was low-serum
potassium. Baseline characteristics consisted of co-morbidities, medications, signs and
symptoms, vital signs, diagnostic data, and information on gender and race. After
matching, participants were studied to determine a relationship between hypokalemia in
the elderly population and mortality or hospitalization. Alper et al. (2009) suggested that
there are limited studies with this age group. Ten percent of the articles in the review of
literature were published in the last 5 years, with approximately 45% in the last 10 years.
Of the 31 articles in their literature review, 61% were published in journals of cardiology
or heart-related journals. Surprisingly, only 6% were published in journals related to
gerontology with other related journals accounting for the remaining 32%. The
researchers identified that hypokalemia may be an indicator of disease progression. In
addition to diastolic and endothelial dysfunction, an increased rate of thrombosis and
platelet aggregation was associated with low potassium (Alper et al., 2009).
Bias was avoided by estimating pre- and post-match absolute standardized
differences of covariates between the two groups. "An absolute standardized difference
of 0% indicated no residual bias, and an absolute standardized difference below 10%
suggested inconsequential residual bias" (Alper et al., 2009, p. 2). In addition to having
absolute standardized differences, McNemar and paired sample t tests compared the
baseline characteristics of matched patients (Alper et al., 2009). "Kaplan-Meier plots and
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matched Cox regression analysis were used to estimate associations of low potassium
with various outcomes" (Alper et ah, 2009, p. 2). According to Alper et al. (2009),
researchers used three different approaches to test for bias: unadjusted, adjusted for raw
propensity scores, and adjusted for all covariates used in the propensity score model. In
addition, they reviewed outcomes for the full pre-match cohort in an effort to show that
decreasing the sample size of the larger study did not skew their data (Alper et ah, 2009).
Findings from this propensity-matched study of ambulatory adults over 65 years of age
diagnosed with heart failure and hypokalemia did have an increase in mortality but not
hospitalization (Alper et ah, 2009). According to Alper et al. (2009), the dissociation
between mortality and hospitalization may have been caused by preventable fatal
ventricular dysrhythmias that precluded the hospital admission.
This study's findings indicate that maintaining a normal serum potassium level of
4.0-4.9 mEq/L in patients with chronic heart failure may improve their survival. They
further stated that spironolactone or eplerenone may be preferable to a potassium
supplement to correct hypokalemia in chronic heart failure patients. A strength identified
in this study was the degree to which the researchers went to match and analyze the data
to avoid any bias or misrepresentations. Weaknesses identified included the lack of data
on dosages of diuretics, magnesium levels, or sudden cardiac deaths (Alper et al., 2009).
This study is significant to the current researchers; interest shows the importance
of monitoring the serum potassium levels and regulating within the desired range of 4.04.9 mEq/L for patients diagnosed with heart failure. Many labs consider 3.5-5.0 mEq/L
normal for most healthy individuals. This study reveals a tighter control of 4.0-4.9
mEq/L is needed to prevent fatal dysrhythmias for patients diagnosed with heart failure.
This study supported the importance of maintaining electrolyte levels within an
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acceptable range in order to prevent hyperkalemia, which could cause detrimental effects
if not controlled.
In a study conducted by Desai et al. (2007), hyperkalemia was indicated as a
serious adverse event in patients diagnosed with heart failure. It can cause many
complications ranging from medical intervention to lethal cardiac arrhythmias. Adequate
renal perfusion is needed to help maintain normal potassium levels through sodium
reabsorption, maintaining normal aldosterone concentrations and normal potassium
channels in the collecting duct system (Desai et al., 2007). A decreased renal function,
associated with age and comorbid conditions, can lower the body's ability to excrete
potassium. Certain medications can also increase the probability of developing
hyperkalemia. Angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor
blockers (ARB), and mineralocorticoid receptor antagonists can reduce morbidity and
mortality with heart failure patients but can increase serum potassium levels (Desai et al.,
2007).
Quantitative data obtained in the Candesartan in Heart Failure-Assessment of
Reduction in Mortality and Morbidity (CHARM) Program was utilized to perform a
retrospective analysis of the incidence and predictors of hyperkalemia with a median
follow-up of 3.2 years. The CHARM Program defined clinically important hyperkalemia
as hyperkalemia requiring medical intervention, such as medication dose reduction, study
drug discontinuation, hospitalization, or death (Desai et al., 2007). The researchers
utilized the Mantel-Haenszel method to determine the incidence of hyperkalemia,
compare treatments, and calculate variable duration, f he Cox proportional hazards
model was used to analyze the timing for development of hyperkalemia requiring medical
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intervention. The Cox model was also used to analyze multivariate predictors, such as
age, gender, medication, and diabetes.
The CHARM Program was compromised of 7,599 participants who were treated
according to standard heart failure guidelines in addition to randomized treatment with a
titrated dose of the ARB candesartan, or placebo. The CHARM Program researched the
benetit and risks of using candesartan, alone and in combination with an ACE inhibitor
(Desai et al., 2007 ). Hie choice of the ACE inhibitor was determined according to the
preference of the investigator with the dosage based on proven clinical trial effectiveness
in addition to patient tolerance. The researchers identified a CHARM Program North
American cohort subset of 2,675 eligible male and female patients, age 18 years and
older, who were diagnosed for at least 4 weeks with symptomatic class II to IV heart
failure according to New York Heart Association Classification guidelines (Desai et al.,
2007).
Patients were evaluated at 2, 4. and 6 weeks; 6 months; and then every 4 months
until the conclusion of the study. The investigators performed serial monitoring of lab
values including potassium and creatinine levels in addition to close observation for
serious complications, such as hyperkalemia. According to Desai et al. (2007), lab values
were assessed prior to the initiation of the medication, again within 2 weeks after the
medication dose was stabilized, then yearly. Ihe investigators also had the option of
performing additional lab monitoring according to their discretion.
The investigators determined that heart failure patients at risk for developing
hyperkalemia, 12.6 per 1,000 patient-years, were males of advanced age with a history of
diabetes, as well as those using an ACE inhibitor or spironolactone. It was also noted
these patients had a baseline potassium level of 5.0 or greater and creatinine of 2.0 or
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greater. The patients at greater risk were those with baseline renal insufficiency,
accounting for more serious hyperkalemia events including hospitalization or death
(Desai et al., 2007). The investigators also concluded patients with creatinine levels of
2.0 or above receiving the placebo were twice as likely to develop hyperkalemia as those
patients with creatinine levels < 2.0 who were receiving the ARB candesartan (Desai et
al., 2007). The investigators concluded serious hyperkalemia episodes occurred in 2.7
per 1,000 patient-years, although the rate could have been elevated to 11.9 per 1,000
patient-years if effective monitoring protocols had not been followed (Desai et al., 2007).
Desai et al. (2007) reported inhibitors of the renin-angiotensin aldosterone system
(RAAS) can decrease potassium excretion, especially in patients with compromised renal
function. Drugs that can hinder the production or action of renin and angiotensin include
non-steroidal anti-inflammatory drugs, beta-blockers, ACE inhibitors, and ARBs. When
used in effective doses, RAAS inhibitors have been noted to reduce morbidity and
mortality outcomes; however, potassium levels can be increased < 1 mEq/1 (Desai et al.,
2007). Spironolactone, an aldosterone receptor antagonist, has also been associated with
hyperkalemia, including associated hospitalizations.
Several limitations were identified by the researchers. Potassium monitoring
guidelines were furnished to the CHARM investigators; however, the decision to manage
the hyperkalemia and report it as an adverse event was left to the judgment ot the
investigator. The definition of clinically important hyperkalemia was not assigned actual
serum potassium values; therefore, the researchers considered the possibility that some
physicians may have managed a tolerable increase in the potassium level or that some
increases in potassium level could have gone undetected. Anothei limitation identified
was that although dose reduction or discontinuation of candesartan due to hypeikalemia

was reported for the trial, hospitalization and death were only identified by investigatorreported adverse event review (Desai et ah, 2007).
Further studies in larger cohorts are needed for more precise hyperkalemia
occurrence rates; however, a strength identified by the researchers was the data provided
by the CHARM Program provided important information regarding hyperkalemia risk in
the management of patients with heart failure. Desai et al. (2007) concluded the periodic
laboratory testing of serum potassium level and creatinine level is important to reducing
adverse events related to hyperkalemia (Desai et ah, 2007).
The research study conducted by Desai et al. (2007) was significant to the current
study of monitoring potassium levels in the treatment of heart failure since it studied the
incidence and predicting factors that are associated with hyperkalemia events associated
with heart failure treatments. Their findings found that hyperkalemia occurred in a large
group of heart failure patients, whether or not they were taking the ARB medication
candesartan (Desai et al., 2007). Certain populations were identified as having a higher
occurrence risk for developing clinically important hyperkalemia. Male patients aged 75
years and older, with a decline in renal function and comorbid medical conditions, have
an increased risk of developing hyperkalemia. Patients with a low left ventricular
ejection fraction were found to be more likely to develop hyperkalemia as opposed to
patients with a left ventricular ejection fraction of 40% or greater (Desai et al., 2007).
The practitioner must understand the affecting risk factors in order to be able to carefully
weigh the benefits of treatment options as it relates to morbidity and mortality rates for
heart failure. Careful monitoring of labs should be perfoimed to help pi event the
development of hyperkalemia in patients treated with heait failuie medications.
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Bowling et al. (2009) performed a quantitative, propensity matched study that
investigated the effects of hypokalemia on patients suffering from chronic heart failure
with the comorbidity of chronic kidney disease (CKD). Sampling data used in the
current study came trom the Digitalis Investigative Group (DIG), a randomized clinical
trial, conducted in the early 1990s. The DIG study consisted of 7,788 patients diagnosed
with chronic heart failure and chronic kidney disease (CKD). Prior research had shown
that hypokalemia and CKD were associated with poor outcomes in heart failure patients.
The researchers evaluated the effect hypokalemia has on patients suffering from both
heart failure and chronic kidney disease.
Of the 7,788 ambulatory patients with chronic systolic and diastolic heart failure
in normal sinus rhythm enrolled in the DIG trial, 6,800 had a left ventricular ejection
fraction < 45% (Bowling et ah, 2009). More than 90% of DIG participants were
receiving angiotensin-converting enzyme inhibitors, and close to 80% were receiving
non-potassium sparing diuretics. Patients with a serum creatinine > 2.5 and serum
potassium > 5 were excluded from the study. After exclusion of the creatinine and
potassium in those ranges, a cohort of 6,278 patients was available for analyses (Bowling
et al., 2009). The researchers further broke down this cohort into those who had chronic
kidney disease. Of the 6,278 patients, 2,793 had a glomerular filtration rate (GFR) < 60
mL/min per 1.73 m2 body surface area (Bowling et al., 2009). Of the 2,793 with CKD,
527 had hypokalemia (serum potassium < 4 mEq/L), and 2,266 had normokalemia (4.04.9 mEq/L) (Bowling et al., 2009). Of particular interest to the current study, using a 1to-1 greedy matching protocol, the current researcheis matched 522 heart failure patients
with hypokalemia to 522 heart failure patients with normokalemia who had similar
propensity scores (Bowling et al., 2009). This study also reviewed patients that were
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considered severely hypokalemic with a serum potassium <3.5 and advanced stages of
CKD with a GFR < 45 mL/min per 1.73 m2 (Bowling et al., 2009). In addition to the
aforementioned, thiee additional cohorts were assembled within the current research.
The dependent variable in the study was the presence of hypokalemia. There were 32
measured baseline characteristics and 2 covariates, creatinine by diuretic use and
creatinine by angiotensin-converting enzyme inhibitor use (Bowling et al., 2009). In
addition to information on age, race, and gender, the baseline characteristics consisted of
diagnostic and radiology results, signs and symptoms, and other objective data. The
researchers were interested in hypokalemia versus normokalemia in the heart failure
patients with CKD as it pertained to all-cause mortality, cardiovascular mortality, and
hospitalizations. The study found that all-cause mortality occurred in 48% and 36%,
respectively, of all 522 patients with hypokalemia versus normokalemia in chronic heart
failure and CKD (Bowling et al., 2009). Cardiovascular mortality for patients with
hypokalemia was 39% as compared to 28% of those with normokalemia. Mortality
related to progressive worsening heart failure was 21% in the hypokalemic patient as
compared to 14% in the normokalemic patient (Bowling et al., 2009). All-cause
hospitalization for heart failure patients with hypokalemia was 72% as compared to 69%
with normokalemia. Cardiovascular hospitalization lor hypokalemia and normokalemia
was 59% and 53%, respectively. Hospitalization related to worsening heart failure was
39% in the hypokalemic patient versus 34% in the normokalemic patient. The
researchers further showed that even mild hypokalemia as defined by serum potassium of
3.5-3.9 in this study and considered normal by many textbooks can be significant to the
patient diagnosed with heart failure. All-cause mortality for the patient with mild
hypokalemia was 47% as compared to 38% of the patients with normokalemia, defined as
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serum potassium 4.0-4.9. All-cause cardiovascular mortality was 39% for the mildly
hypokalemic patient versus j0% with normokalemia. Thirty percent of the patients with
mild hypokalemia expiied from worsening progressive heart failure versus 13% of those
with normokalemia. Sixty-five of the 522 patients in this study had more severe
hypokalemia as defined by serum potassium levels below the 3.5 mEq/L range. Thirtyone percent of patients with severe hypokalemia died from events related to worsening
heart failure in comparison to 14% of those with normokalemia. The theoretical
framework used in the study was not evident; however. Roy's Adaptation Model (RAM)
by nurse theorist Sister Callista Roy could be considered here. This theory can be applied
because of the physiological-physical mode, one of four adaptive modes identified by
Roy. This mode consists of the need for fluid and electrolyte balance along with the
process of maintaining homeostasis of the body's internal environment.
The statistical analysis was performed using SPSS version 15 for Windows, a
computerized statistical package. For descriptive analyses, the researchers used Pearson
X2 and Wilcoxon rank sum tests for the pre-match data and the McNemar test and paired
sample t test for post-match comparisons. Kaplan-Meier plots and matched Cox
regression were used in estimation of hypokalemia with other outcomes. To determine
the homogeneity of hypokalemia with all-cause mortality among patients with heart
failure and CKD, the researchers examined the association in various subgroups of
matched patients (Bowling et ah, 2009).
Due to this study being conducted through a retrospective chart review, the
researchers did not interact with participants from the DIG trial. Therefore, no data were
outlined in the study as to how the participant's rights were affected. A particular
weakness identified was the exclusion of data on the dosages of diuretics. The inclusion
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of dosing regimens would have been an added strength (Bowling et ah, 2009). Many
believe that the signs and symptoms of heart failure are strongly associated with the
dosage of the diuietic. Another limitation to this study was that no data were provided on
the B-type natiiuietic peptide levels (BNP) which could have provided further
information on the severity of heart failure (Bowling et ah, 2009). In addition to absence
ol data regarding the BNP, no data existed on the use of beta-blockers due to the fact that
they were not approved at the time of the original research from which this dataset was
extracted. Strengths of the study were to bring attention to the public and healthcare
professionals about the imperative monitoring of serum potassium levels in heart failure
patients with CKD. "In ambulatory patients with chronic heart failure and CKD,
hypokalemia is associated with increased mortality and hospitalization. Research shows
that even mild hypokalemia defined as 3.5-3.9 for heart failure patients with CKD are
associated with poor outcomes" (Bowling et ah, 2009, p. 259).
This article statistically shows the percentage of mortality and hospitalizations
related to both mild and severe hypokalemia. "Hypokalemia is known to enhance
membrane excitability, increase cardiac automaticity, delay ventricular repolarization and
predispose patients to reentrant arrhythmias" (Bowling et ah, 2009, p. 258). For this
reason, it is imperative that practitioners follow the guidelines to maintain the potassium
levels of heart failure patients between 4.0-5.0 mEq/Liter. Serum potassium should be
monitored and maintained in this range to avoid even mild hypokalemia in patients with
heart failure that also have chronic kidney disease. Ihe importance of iollowing cuiient
heart failure guidelines combined with a thorough physical exam piotocol toi the general
medical profession is imperative in order for continuity of care and preventative
treatment outside the hospital setting.
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In a study by Aranda, Johnson, and Conti (2009). heart failure was shown to
affect approximately 5 million adults in the United States. In 2008 heart failure costs
were an estimated $J4 billion. The researchers concluded that 12 to 15 million office
visits and 6.5 million yearly hospital days can be attributed to heart failure, despite
improv ements in treatment with medications, such as angiotensin-converting enzyme
inhibitors, B-blockers, and aldosterone antagonists. Patients hospitalized with a
diagnosis of heart failure are at a higher risk for readmission within 6 months—as high as
50% (Aranda et ah, 2009).
The investigators utilized a retrospective, observational study to estimate current
rates of readmission for Medicare patients with heart failure, identify the reasons for
these readmissions, and identify associated factors related to increased risk of
readmissions. The information was gathered from 2002-2004 Medicare data obtained
from the Centers for Medicare and Medicaid Services. Although previous studies on
readmission rates have been useful, those results have often been limited to single-center
experiences which are not representative to the general population current practices.
According to Aranda et al. (2009), a 5% sample was created by selecting records with a
health insurance claim number ending in 05, 20, 45, 70, or 95. This type of sampling
technique provided consistency, allowing the researchers the ability to identify records
associated with the same beneficiary across several years. All patient information,
recorded by a calendar-year quarter, included hospital dischaige during 200J with an
ICD-9 discharge code of 428.0 through 428.9 (heart failure) or 398.91 (lheumatic heait
failure).
Aranda et al. (2009) limited baseline patient characteristics to age, gender, race,
comorbidities, and geographical location. Other baseline characteristics considered were
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previous hospitalizations, length of stay for the initial heart failure hospitalization,
implantation ol a pacemaker or cardioverter-defibrillator during the initial heart failure
hospitalization (Atanda et ah, 2009). A multivariate logistic regression method was
utilized to examine the associations between the baseline characteristics and rates of
readmission. Readmission rates within each of the characteristics were compared after
calculating odds ratios.
The researchers' investigation identified 28,919 patients which totaled 38,849
heart failure hospitalizations in the 2003 Medicare sample. The identified patient data
revealed 51% with one or more hospitalizations for any cause in the 6 to 9 months prior
to the first heart failure hospitalization. Patients with a previous heart failure
hospitalization in the preceding calendar year totaled 18%, while 6% of patients had two
or more previous heart failure hospitalizations. Utilizing this information, the researchers
were able to predict an estimated 776,980 hospitalizations involving 578,380 patients
(Aranda et ah, 2009).
According to Aranda et al. (2009), heart failure accounted for the most frequent
reason of all hospital readmissions, totaling 28% during the review period. 1he patients
in the 65 years and older age group comprised 89% of the sample selection. The data
also revealed that 83% were Caucasian, 56% were female, and 37% had a comorbidity of
diabetes. Patients who resided in the southern region of the United States totaled 41%,
which was the highest of any demographic rate.
The researchers used a multivariate logistic regression model to identity factois
associated with readmission for any cause within 6 to 9 months of the initial heart failure
hospitalization. Aranda et al (2009) determined that 60% of the patients had at least one
readmission, with an average of 2.2 readmissions noted per patient. The data revealed
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patients >ounger than 65 years of age had a decreased probability of readmissions within
6 to 9 months as compaied with patients 65 to 85 years of age. Caucasian patients had a
higher risk foi readmission as compared to minority patients. Patients diagnosed with
heart taiiure had a highei occurrence of comorbidities, which will also influence
readmission lates. However, findings of the study indicated that patients diagnosed with
hypertension, or those who received an implanted cardiac device at the time of the initial
heart failure hospitalization, had a lower risk of readmission (Aranda et al., 2009). The
population included in this study had a mean length of stay of 5.4 to 5.5 hospital days.
1 he researchers also determined the patients in the sample population had a 4.4% inhospital mortality rate, and approximately 8% of the patients that were not readmitted
died within the first 6 to 9 months after the initial heart failure hospitalization (Aranda et
al., 2009).
One of the study's limitations identified by the researchers was that there was a
lack of extensive clinical information which prevented detailed evaluations, such as
identifying New York Heart Association (NYHA) classification or disease severity.
Another limitation identified was that the information from the sampling of Medicare
claims in the Medicare Standard Analytical File Limited Data Set did not provide an
exact date of each hospitalization, making it difficult to identify discharges in 2003.
Although this is done to help protect patient privacy, it can lead to certain challenges
when a patient had other hospitalizations during the same calendai-yeai quaitei (Aianda
et al., 2009).
The strength of this study was the use of a large public health database to identify
current trends in healthcare, such as readmission rates for heart failure patients. This
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resource can help identify associated factors that lead to poor outcomes after the initial
heart failure hospitalization (Aranda et ah, 2009).
The ieseaich study conducted by Aranda et al. (2009) was important to the current
study of monitoring potassium levels in the treatment of heart failure. The study
confirms that despite improved medication options and evidence-based treatment
guidelines, heart failure patients continue to experience an increased chance for disease
exacerbation. Aranda et al. (2009) concluded that individuals with heart failure have a
60% hospital readmission rate, as well as significant mortality rate. It is important for the
healthcare provider to identify this high-risk population in order to decrease the
possibilities of comorbidity events, such as monitoring alterations in potassium levels
which could cause life-threatening arrhythmias. Therefore, increased awareness and
education are needed for the appropriate treatment of heart failure patients, while at the
same time helping decrease the economic burden associated with this disease.
In a study conducted by Dunlay et al. (2010), heart failure is an ever-increasing
economic burden on the United States healthcare system. Medical care costs have risen
over the years and are projected to continue to rise partly due to an aging population, a
rise in the diagnosis of heart failure, and additional co-morbid conditions. Heart failure
treatment constituted an estimated $37 million in 2009 and consumed more U.S.
Medicare dollars than any other diagnosis (Dunlay et al., 2010). Despite what is known
about hospitalization care costs, much less is known about the cost of outpatient medical
care.
Dunlay et al. (2010) investigated the estimated lifetime costs from heart failure
diagnosis until death. The study was conducted in Olmsted County, Minnesota, from
1987 to 2006. Medical records from 97% of the population involving all care sources
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were indexed and linked in a centralized system known as the Rochester Epidemiology
Project database. This database contained medical record information and billing
information tor hospitalization, surgery, and outpatient visits.
This cohoit longitudinal study identified residents with a diagnosis of heart
failure using the ICD-9 code 428. Patients were excluded from the study if heart failure
was diagnosed prior to the study period or diagnosed before moving to the county.
Records were reviewed by abstractors to ensure that all criteria and diagnosis
documentation were present. A total of 1,054 heart failure patients were randomly
sampled. The baseline characteristics of the population were 46.1% male with a mean
age of 76.8 years. The mean follow-up was conducted at 4.6 years and found that 765
patients had died (Dunlay et al., 2010).
After cases were identified and grouped into the appropriate heart failure
category, the lifetime costs data were estimated using the 2-part Tian and Huang method.
The first part of the model estimated the probability of having positive costs. The second
part of the model uses generalized linear methods to pattern the lifetime costs in the event
of positive cost. A similar 2-part model was used to determine the independent
predictors of lifetime costs by predicting inpatient, outpatient, and total costs (Dunlay et
al., 2010).
The investigators' data revealed 77% of the costs were due to hospitalization with
an average of $73,762 per person, while outpatient costs averaged $22,032 per person
with the highest proportion stemming from evaluation, management, and piocedures in
the provider's office. Certain co-morbid conditions, such as (a) hypertension, (b) renal
disease, (c) COPD, (d) anemia, (e) diabetes mellitus, and (f) cerebrovascular disease,
which could lead to or exacerbate heart failure, were found to increase the costs. The
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researchers determined that the distribution of costs were high at the time of initial
diagnosis and decreased and remained relatively low until the end stage of the heart
failure disease process when costs increased again. The investigators further analyzed
the cost effect by comparing healthcare costs in the year prior to the diagnosis of heart
failure with the year beginning with the diagnosis. A mean total cost of $8,000 per
pet son was noted piior to the diagnosis, with a marked increase of a mean total cost of
$34,000 per person in the year after diagnosis (Dunlay et al., 2010).
One limitation to the study was the fact that the researchers identified only direct
medical care in interpreting the data. The investigators did not include indirect costs of
care or outpatient medications in research. Another limitation identified was that some
costs may have been underestimated if a patient received medical care outside the
community due to travel or other extenuating circumstances. Although the researchers
did not compare lifetime costs of care with a control group of patients without heart
failure, there is evidence of a marked increase in the costs of care post-diagnosis of heart
failure in the same patients as compared to before the diagnosis. The researchers also
acknowledged that the results related to a single geographical area; however, the ability
to examine lifetime costs of medical care in a stable population provides valuable
information. Despite the limitations identified, the researchers acknowledged this study's
importance in determining the distribution of resources and cost and various patient
characteristics that can predict high or low costs. The strengths included the use of a
validated population of heart failure patients followed longitudinally and the inclusion ot
both inpatient and outpatient costs of healthcare costs (Dunlay et al., 2010).
The research study conducted by Dunlay et al. (2010) further supported the
significance of conducting the current study of monitoring potassium levels in the
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treatment of heart failure by identifying factors associated with higher medical costs.
This can be helpful in targeting patients in order to carefully prevent or treat certain comorbid conditions, improve quality of care, and avoid inpatient admissions to help reduce
healthcare costs. 1 his study suggested these are key areas for the practitioner to focus
appropriate medical intervention in the treatment and management of heart failure.
Fonarow et al. (2012) performed a mixed study with a nested matched casecontrol design using data retrieved through retrospective chart review. The current study
obtained data from the longitudinal, cohort study, Registry to Improve the Use of
Evidence-Based Heart Failure Therapies in the Outpatient Setting, known as (IMPROVE
HF). IMPROVE HF is one of the largest heart failure studies. There has been limited
research exploring the application of guideline-recommended therapy with clinical
outcomes in patients with heart failure (Fonarow et al., 2012). The researchers in this
study sought to discover the individual and incremental gains associated with each of
seven current guideline-recommended therapies for heart failure and reduced left
ventricular ejection fraction (LVEF) (Fonarow et ah, 2012). The seven guidelinerecommended therapies consisted of the following: (a) angiotensin converting enzyme
inhibitor or angiotensin receptor blocker (ACEI/ARB), (b) beta-blocker, (c) aldosterone
antagonist, (d) anticoagulation for atrial fibrillation/flutter, (e) cardiac resynchronization
therapy (CRT) with a pacemaker or defibrillator, (f) implantable cardioverter-defibiillator
(ICD or CRT with defibrillator), and (g) patient education about heart failure (Fonarow et
al., 2012).
The researchers sought to define the significance or value of each individual
therapy as recommended by the guidelines.

The primary analysis was designed to

evaluate the association of baseline use of the seven guideline-recommended heart failure
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therapies and mortality within 24 months and follow-up" (Fonarow et ah, 2012, p. 18).
In addition, the researchers measured the probability of death in patients eligible for
therapy versus those not receiving any treatment. Investigators sought to determine the
association between the total number ol guideline-recommended therapies received by all
patients at baseline and death within 24 months (Fonarow et al., 2012). The sequential
contribution of ACEI/ARB, beta blockers, cardiac ^synchronization therapy (CRT), and
ICD were analyzed. A defined theory was not explicit.
The population of patients from which the current study derived was 15,177 of the
original participants enrolled in IMPROVE HF. Eligibility criteria to participate in the
study included a clinical diagnosis of heart failure or prior myocardial infarction, with a
LVEF < 35%. Initially, a random sample beginning with approximately 90 participants
from 167 clinics across the United States was available prior to propensity matching.
The sample of participants for this current study was 4,128 after the propensity score
matching process. This sample was then divided into two groups: (a) those that had
expired from any cause before 24 months and (b) those alive at 24 months. The
participant group which expired was defined as cases, and the group alive at 24 months
was referred to as controls. The sample of 4,128, after division into cases and controls,
were 1,376 and 2,752, respectively. Propensity score matching on the case and control
groups was completed using a 1:2 greedy-matching. Between the two groups, the
participants were well-matched with race being the only statistically significant
difference (Fonarow et ah, 2012). The majority of the outpatient practices was not
affiliated with a university or teaching facility and was well-matched with the number of
individuals on staff (Fonarow et ah, 2012). The probability of death was the propensity
score in this analysis. A logistic regression model was used to generate the probability of
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death. The outcome consisted of deceased versus those alive. Covariates consisted of 22
baseline patient characteristics and 4 practice characteristics. "Patients who met the
guideline eligibility criteria for each individual therapy, with no contraindications,
intolerance, or other documented reasons for not receiving it, were eligible for inclusion
in the analyses for that measure" (Fonarow et al., 2012, p. 18). To qualify for an
aldosterone antagonist, CRT, or ICD therapy, documentation of the New York Heart
Association functional class must exist in the medical record (Fonarow et al., 2012).
Chart reviewers received training from members of the IMPROVE PIF committee to
ensure abstraction ot data was accurate (Fonarow et al., 2012). A report on data was
generated on a monthly basis during data collection over the 24-month period. In
addition, an audit was completed on 20% of all participant data. Thorough matching and
education of chart reviewers helped to avoid bias. However, socioeconomic factors or
patient adherence to therapeutic regimens could not be adjusted (Fonarow et al., 2012).
The two-sample t test and chi-square test were used for analysis of the continuous
variables and categorical variables, respectively. Baseline treatment rate was calculated
for the case and control groups. Differences between the two were compared using the
chi-square test (Fonarow, et al. 2012). Initially, "an unadjusted odds ratio (OR) of death
was determined using a logistic regression model with the therapy the predictor variable
and no covariate adjustment" (Fonarow et al., 2012, p. 18). Further analysis to identify
potential covariates was completed with the use of a univariate logistic regression model
(Fonarow et al., 2012). Characteristics with a value < .10 in the univariate regression
were fit into a multivariate regression model with treatment as the main etiect. 1 hetapies
were listed in order of how commonly prescribed in clinical practice from greatest to
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guidelines recommend serum potassium monitoring with the use of these medications.
Without monitoring ot potassium by healthcare providers in patients prescribed these
medications, a patient may die as a result of serious electrolyte abnormalities. Fonarow
et al. (2012) stated that independently valuing heart failure therapies would enable a
provider to make the best decision on which medicine to continue or discontinue if a
choice must be made for leasons of cost, tolerance, or adherence. In addition, many
hospitals and clinics provide performance improvement programs to ensure that
guideline-recommended therapies are utilized.

Conceptual Framework
Several studies have focused on the use of Sister Callista Roy's Adaptation
model. The innovative work of Sister Callista Roy, RN, PhD. presented the nursing
theory that views the individual as a holistic adaptive system as related to the concepts of
person, health, environment, and nursing. Roy's Adaptation Model (RAM) is aimed at
understanding human behavior in order to maintain and enhance coping mechanisms to
promote optimal health. RAM can be applied not only to the individual, but it can be
easily adapted to group situations. The current research group reviewed one original
article by Sister Callista Roy and three additional research articles using the Roy
Adaptation Model as the theoretical framework. The current researchers demonstrated
how these researchers utilized Roy's Adaptation Model to guide their studies as well as
discuss how the Roy Adaptation Model was used as the foundation of the current
research study.
As a graduate student in 1964, Sister Callista Roy saw the person as an entity,
which not only persisted on the individual self, but included the environment as a whole
contributing to the health and well-being of the person holisticallv. She believed that the

portal to human health was not only for nurses to care for the person physically but to
incorporate environment, beliefs, roles, economics, and population-based care into the
equation. Nursing exists as an academic discipline and a practice profession, and both
rely on timely knowledge development. People of today's society have evolving needs
that increase the complexity of care, such as a) chronic illnesses due to increasing
longevity, (b) rising ethnic and racial populations, and (c) global economic status. Nurses
must work for the common good and dignity of people within their realm of existence. In
order to accomplish this task, Roy reevaluated the RAM to bring nursing care into the
21 century and beyond. "The social mandate of nursing is to contribute to the good of
society by knowledge-based practice related to contemporary and emerging health needs"
(Roy, 2011, p. 1). Roy devised Epochs to extrapolate past thought to modern times in
order to describe the needs and thoughts relevant to each Epoch period. Roy integrated
Laszlo's view of the human brain when he described it as a quasi-neural energyinformation-processing network into a view of nursing around the globe that interacts
with each other, to nature, and reality. This allows existing and future nurses to view the
increasing role of knowledge expansion and care expectations placed on the nursing
society as a whole. In addition, it allows nurse practitioners to build upon the solid
foundation of knowledge that has been established in previous years tor use in today s
21st century.
Thomas (2007) reviewed a study on how self-concept has negative impacts on
treatment modalities in patients with heart failure. Although there have been many
surgical and medical advances in heart failure, pool adherence to recommended diet,
exercise, and medication regimens continue to negatively impact outcomes (Thomas,
2007). The RAM was used to guide this study in which Roy emphasized that self-
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concept or the perceptions that one holds of oneself directs behavior. Roy identified five
different aspects on self-concept which include body image, body sensation, self-ideal,
self-consistency, and moral-ethical-spiritual self (Thomas, 2007). A descriptive
correlational design was used to assess if there was a correlation between self-concept
and treatment modality compliance. Two heart failure clinics were included in the study.
One clinic was located in a rural/suburban area, and the other was located in a large urban
inner city (Thomas, 2007). Patients who met criteria for the study were asked questions
as they visited the clinics. Descriptive and predictive correlational analysis, using the
Pearson product moment correlation and the stepwise multiple regression were used to
analyze the answers. The overall threat to self-concept was 12% (p < .01), threat to body
image was 14% (p < .01), challenge to self-concept was 13% (p < .01), and challenge to
moral-ethical-spiritual self and body image was 14.5% (p < .01) with the challenge to
moral-ethical-spiritual self and body image being the strongest predictor of adherence to
health regimens (Thomas, 2007). Using a theory-based nursing study helps us
understand how self-concepts influence treatment modalities for HF patients. In addition,
it identifies the imperative need for positive reinforcement, praise, and education.
Abbas, Schahanz, and Saeed (2011) embarked on a study in Iran using RAM in
attempts to describe the adherence to therapeutic regimens in patients with heait tailuie.
As described in a previous study using the RAM, noncompliance to heart lailure
treatment has become global. A descriptive correlational study was conducted in two
medical centers in Iran with questionnaires filled out by paiticipating patients who met
the qualifying criteria. Results showed the following analysis: 33% were female with
average age 62 years, 80.6% were married, 56.9% used medications, 54.9% did not use
medications, and 39.0% exercised. The findings of this study showed that a viewed
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threat to the components of self-concept (including body sensation, body image, selfconsistency, self-ideal, and moral-ethical-spiritual self) has a negative relationship with
regimen adherence, whereas a viewed challenge to self-concept and its components is
positively related to the adherence (Abbas et al„ 2011). Nurses around the world should
assess the outcomes ot this study and others as well in order to involve patients in their
treatment regimens. Sistei Callista Roy has modernized the RAM to incorporate a more
consistent global lesponse between all members of the medical profession in order to
tonn a smoother transition from a noncompliant society due to decreased knowledge of
the disease process and treatments to a better educated and involved compliant society.
Bakan and Akyol (2007) did an interesting study that examined the effectiveness
ot a RAM as a useful guide for nursing practice when caring for heart failure patients.
The researchers utilized data from a secondary analysis of a randomized-controlled trial
to determine how programs such as education, exercise, and social support impacted
adaptation in patients with heart failure (Bakan & Akyol, 2007). The information was
obtained by utilizing the Minnesota Living with Heart Failure Questionnaire. The study
was directed by the RAM, which focused on environmental stimuli and the associated
response modes to those stimuli (Bakan & Akyol, 2007). The four biopsychosocial
modes used to measure the level of adaption are physiological mode, self-concept mode,
role function mode, and interdependence mode. The authois established that patients
with physical, emotional, social, and economic difficulties can have impaired coping
mechanisms. Intervention groups for the four modes of adaptation were established to
monitor and improve coping mechanisms. RAM is an important theory concept guide in
the care of patients who have been diagnosed with heart failure. This article corroborates
the need to incorporate RAM into patient education programs to enhance the patient's
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knowledge and skills necessary to evoke behavior changes for appropriate coping of this
long-term health problem. Using the Roy Adaptation Model, patients who had
participated in the intervention group had improved emotional status and quality of life,
increased functional abilities, and enhanced social support (Bakan & Akyol. 2007).
Adaptation involves coping mechanisms to control internal and learned
environment. The mechanisms for coping can be learned or inherited (George, 2011).
R°y developed the concept of control mechanisms. Through her model, she classifies
these mechanisms of coping as subsystems of the person's adaptive function (George,
2011). Of significance to the current research project are the regulator and cognator
subsystems and the physiological-physical mode, one of four developed by Roy's model.
Rogers and Keller (2009) stated the effects of coping at the subsystem level cannot be
measured. "The cognator subsystem involves four cognitive channels: perceptual and
information processing, learning, judgment and emotion" (Rogers & Keller, 2009, para.
8). Noncompliance with medication adherence and follow-up for serum potassium
monitoring could be a result of cognitive impairment. Three components of the regulator
subsystem include input, internal process, and output. It contains transmitters that can be
characterized as chemical, neural, or endocrine. Work of breathing and regulatory
feedback mechanisms of respiration and heart rate, the regulator subsystem, can be
evident in patients with heart failure. Fluid and electrolyte balance, oxygenation,
activity/rest and nutrition are complex processes of the physiological-physical mode.
Rogers and Keller (2009) stated that, "stimulation to the regulator and cognator
subsystems result in behavior changes measuied in the physiologic and psychosocial
modes" (para. 8). Through monitoring of the potassium level in patients with heart
failure and bringing an increased awareness to the national guidelines, the current
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researchers will identify how providers can stabilize the internal environment. In
addition, patients must be able to cognitively process information discussed with them on
heart failuie education. Neurologically, their memory must be intact with an appropriate
attention span. They must be able to adhere to follow-up visits for the monitoring of their
potassium level, oui main intracellular electrolyte. Through the current study, these
researchers will be more aware of our future patients' need for regulation of potassium
levels and the need to positively reinforce follow-up.

Summary
The need to monitor serum potassium level is shown to be clinically significant in
the outpatient setting. The review of literature clearly demonstrates that without
providers monitoring the body's main intracellular electrolyte, death could occur.
Evidence shows that ventricular arrhythmias could cause sudden death or increased
mortality related to either hypokalemia or hyperkalemia. The 2009 ACCF/AHA
guidelines should be followed by all providers in the outpatient setting with routine
monitoring of all heart failure patients.

CHAPTER III
Design and Methodology
The locus ol this study was to evaluate healthcare providers' compliance with the
recommended 2009 ACCF/AHA guidelines for monitoring routine serum potassium
levels in heart failure patients. An alteration in potassium levels, either hyperkalemia or
hypokalemia, can cause severe cardiac arrhythmias. The results from this study could
help healthcare piovideis ettectively manage heart failure according to the guidelines and
prevent life-threatening complications that can affect heart failure patients.
I he occurrence ot primary care providers' monitoring potassium levels in the
treatment ot heart failure was determined by using a nonexperimental, quantitative
design. Data were retrospectively obtained from a population sample of 200 charts of
adult patients, 18 years of age and older, with the diagnosis of heart failure, ICD-9
diagnosis code 428. The data were collected from the patient's electronic medical record.
A standardized data collection worksheet was implemented to obtain all information.
Specific data concerning the serum potassium level, frequency of collection, medication
utilized, medication adjustment done if the serum potassium was out of range, age,
gender, ethnicity, and payer source were obtained. In order to maintain the facility s
records and ensure that each patient's right to privacy and confidentiality weie pieserved,
all data collection will be conducted in a designated area of the facility.

Population, Sample, and Setting
The population in this study was any adult patient with the diagnosis of heart
failure identified with ICD-9 diagnosis code 428. Only adult patients, 18 years of age
and older, with a diagnosis of heart failure were selected for the evaluation of potassium
monitoring. The researchers manually obtained a convenience sample of 200 charts from
40
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two rural primary care clinics in north and east central Mississippi with an ICD-9
diagnosis code 428.
Implementation of the Project
Protection of human rights. Prior to the collection of data, the researchers
received written approval by the Mississippi University for Women's Institutional
Review Board (IRB) (see Appendix C). Consent was obtained from the two primary care
clinics in north and east central Mississippi where the data was collected for this study.
The researchers obtained informed consent from each facility's director via a consent
letter (see Appendix D) identifying the purpose and nature of the study. This research
was retrospective chart review only and involved no disclosure related to human
participants. Patient confidentiality was maintained at all times. Access to medical
record numbers, names, date of birth, diagnosis, and other personal information was
limited to the researchers. The research data collection worksheet (see Appendix E)
contained no personal information, such as name, date of birth, or social security number.
Data obtained from the data collection worksheet were stored on two password-protected
media drives that were purchased explicitly tor this purpose.
Data collection procedure. Utilizing the medical records, the researchers
performed a query and collected a list of patients with an ICD-9 diagnosis code 428.
Only charts with ICD- 9 diagnosis code 428 for heart failure were selected for review in
this study. The data were obtained from charts of documented medical care provided to
patients with heart failure. After the list was collected, the researchers manually
reviewed a convenience sample of the first 200 medical records meeting the sample
criteria for this study.
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Once the sample was selected, a chart audit was performed using the standardized
data collection worksheet to obtain data for sample inclusion. The researchers completed
the chart reviews in a secluded area of the clinic. This area allowed privacy and did not
impede patient flow.

The data collection worksheets were stored on two password-

protected media drives purchased explicitly for this purpose. Each researcher remained
in possession ot her tespective media drive and kept it in a locked box for safekeeping.
The password was only known to the researcher. After the data had been compiled and
the completed data collection worksheets were no longer needed, the media devices and
worksheets were destroyed.
Instrumentation. The researchers developed a standardized data collection
worksheet. This worksheet allowed the following information to be collected in a
systematic method: (a) diagnosis of heart failure; (b) the serum potassium level; (c)
frequency of collection; (d) medications to include ARBs, ACE-I, aldosterone antagonist,
diuretics (potassium-sparing, loop, or thiazide), and beta-blockers; (e) was a medication
adjustment made if the potassium level was out of the recommended range; (f) age; (g)
gender: (h) ethnicity; and (i) payer source. The data collection worksheet was used to
evaluate each patient's chart for eligibility of inclusion in the sample. This data
collection worksheet was utilized solely for the purpose of this reseaich study.
Data Analysis
After compilation, data pertaining to the research questions were analyzed using
descriptive statistics. The researchers utilized assistance of a professional statistician to
further correlate categorized percentiles and frequencies to answer the research questions.
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Summary
The importance ot monitoring routine potassium levels in the treatment of heart
failure needs to be emphasized. Once consent from the two rural primary care clinics in
north and east central Mississippi was obtained to conduct the study, the researchers
performed a nonexperimental, descriptive retrospective chart review on 200 medical
charts. 1 he sample w as chosen by use of a convenience sample. Confidentiality and
protection of human rights were maintained at all times. The researchers utilized a data
collection worksheet to gather information needed for descriptive statistics and
correlation analysis to answer the research questions. Data were gathered from the
patient records and analyzed descriptively to answer each of the research questions. The
nominal data were accumulated and presented to a statistician or entered into a computer
database for analysis.

CHAPTER IV
Research Findings
The purpose of this study was to evaluate healthcare providers' compliance with
the recommended 2009 ACCF/AHA guidelines for monitoring routine serum potassium
levels in heart failure patients. In addition, the researchers evaluated if the routine serum
potassium level was documented at least every 4 months as recommended by the ICSI
Guidelines for Heart Failure in Adults. In this chapter, the sample will be described and
the research questions will be answered utilizing the findings from the study.
Profile of Study Participants
A convenience sample of 200 charts ( N = 200) with an ICD-9 diagnosis code 428
was obtained from two rural primary care clinics in north and east central Mississippi.
The data were manually extracted and recorded on a data collection worksheet designed
by the researchers. Charts were not selected earlier than 2009 due to ACCF/AHA
updated guidelines. Subsequent analyses of the data were performed using Minitab
statistical software, version 16. The population sample was eligible for inclusion in the
study when data collection instrument criteria were met.
The sample population included both male and female individuals 18 years of age
and older. The mean for the ages collected was 75 years, with ages ranging from J5-98
years. The median age of the data set was 78 years.
Participant Characteristics
The first question on the researchers' data collection worksheet was in regard to
gender. The sample consisted of 51.5% females ( n = 103) and 48.5% males ( n = 97).
Figure 1 illustrates the percentage of the gender in the sample population.
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Figure I. Gender of sample population (TV = 200).

1 he second question on the researchers' data collection worksheet was in regard
to age. 1 he sample consisted of patients between the ages of 35 and 98 years. The mean
age was 75 years. No patients with an ICD-9 diagnosis code 428 in the age range of 1830 years were identified. Ages 31 -50 years consisted of 4.5% (n = 9), ages 51 -70 years
consisted of 26% (n = 52), and ages 71 and greater consisted of 69.5% (n = 139) of the
sample. Figure 2 demonstrates the age range of the sample population.
The third question on the researcher's data collection worksheet was in regard to
ethnicity. Of the sample collected, 79.5% (n = 159) were Caucasian, 20% (n = 40) were
African American, and 0.5% (n = 1) were other. No Flispanic patients with the ICD-9
diagnosis code 428 were identified. Figure 3 depicts the ethnicity of the sample
population.
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Figure 2 . Age of sample population.
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Figure 3. Ethnicity of sample population.
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The researchers also assessed the sample population's payer source on the data
col l e c t i o n w o r k s h e e t . O f t h e s a m p l e c o l l e c t e d , 9 2 % ( n = 1 8 4 ) h a d M e d i c a r e , 0 . 0 1 5 % ( n
= a) had Medicaid, 0.06% (n = 12) had commercial insurance, and 0.005% (n = 1) was
self-pay. Table 1 is used to illustrate these findings.
Table 1
Payer Source of Sample Population

Payer source

%

Medicare

92.000

Medicaid

.015

Commercial insurance

.060

Self-pay

.005

Results of Data Analysis
According to the 2009 ACCF/AHA guidelines, patients with heart failure, ICD-9
diagnosis code 428. should have routine monitoring of serum potassium levels. The
recommendations state the serum potassium level should be maintained between 4.0-5.0
mEq/L.
The ICS I Guidelines for Heart Failure in Adults were utilized to define routine
monitoring as at least every 4 months. If the serum potassium level was not in the
recommended range of 4.0-5.0 mEq/L, the researchers assessed if there was a medication
adjustment. The following figures will illustrate the statistical findings of the research
questions.
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Research question 1. Was the serum potassium level in patients being treated for
heart tailuie monitoied and documented at least every 4 months as recommended by the
Institutes for Clinical Systems Improvement Guidelines for Heart Failure in Adults? Of
the 200 charts reviewed, 187 had documentation of a serum potassium level checked in
the past four months. 1 his corresponds to a 93.5% compliance rate with the
recommendation by the ICSI Guidelines for Fleart Failure in Adults. Figure 4 is used to
illustrate these findings.

Non-compliance

Figure 4. Frequency of serum potassium documentation.

Research question 2. Was the serum potassium level in the recommended range
of 4.0-5.0 mEq/L according to the 2009 ACCF/AHA recommended guideline when
monitored? Of the 187 charts reviewed in which a serum potassium level was checked
within the pas, 4 months. 142 charts had a documented serum potassium level between
4.0-5.0 mEq/L. This represents 75.9% compliance with the recommended range, and
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24.1% (n

45) outside the recommended range. Figure 5 is used to illustrate the

findings.

• Between 4.0-5.0 mEq/L

Outside the recommended range

24.1%

Figure 5. Percentage of patients' serum potassium level within the recommended
range.

Research question 3. If the serum potassium level was not in the recommended
range, was there a medication adjustment? Of the 45 charts reviewed in which the seium
potassium level was outside the recommended range. 55.6% (n — 25) of the patients did
receive a medication adjustment. The remaining 44.4% (n — 20) ol the patients did not
receive a medication adjustment. Figure 6 is used to illustrate the findings.
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Figure 6 . Percentage of patients outside the recommended range receiving a
medication adjustment.

Conclusion of Findings
1 he data collected in the retrospective chart review was analyzed using
descriptive statistics. This study utilized both tables and figures to present and describe
the findings. Of the 200 charts reviewed. 93.5% (n = 187) of the sample population had
documentation of a serum potassium level within the last 4 months. Of the 187 patients
with documentation of a serum potassium level, 24.1% (n = 45) had a serum potassium
level outside the recommended range of 4.0-5.0 mEq/L. However, out of the 45 patients
who were not within the recommended range, only 55.6% (n — 25) received a medication
adjustment to help correct the electrolyte imbalance. In conclusion, the primary care
providers had a 93.5% compliance with serum potassium monitoring and medication
adjustment if needed according to the 2009 ACCF/AHA guidelines in regard to the total
sample population (N = 200). However, this study revealed there is an opportunity
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among healthcare pio\ iders lor improvement in the routine monitoring of serum
potassium level.

CHAPTER V
1 he Outcomes
Implications

I lean failure is a common complication of heart disease as a result of damage to
the heart muscle. It is a chronic, progressive condition in which the heart muscle
becomes too weak to efficiently pump an adequate amount of blood to meet the body's
need toi blood and oxygen. Increasing prevalence, hospitalizations, and death rate have
made CI If a major chronic condition affecting all ages and races. A review of literature
was completed and demonstrated that heart failure is an overwhelming disease in the
United States affecting millions. Also, it revealed that suboptimal treatment relates to
increased hospitalization and office visits. According to the Healthcare Cost and
Utilization Project of 2009, heart failure was listed among the top 10 most frequent
principal diagnoses utilized (Wier et ah, 2011). Many medications used in the treatment
of heart failure can alter the body's serum potassium level. Potassium plays a critical role
in the heart's electrical conduction, affecting cardiac automaticity and membrane
excitability, as well as repolarization (Bowling et ah, 2009). Heart failure patients should
maintain a serum potassium level in the 4.0-5.0 mEq/L range to help prevent potentially
life-threatening cardiac arrhythmias (Jessup et ah, 2009).
The purpose of this study was to evaluate healthcare provider's compliance with
the recommended 2009 ACCF/AHA guidelines for monitoring routine serum potassium
levels in heart failure patients. In addition, the researchers evaluated if the routine serum
potassium level was documented at least every 4 months as recommended by the ICSI
Guidelines for Heart Failure in Adults. Sister Callista Roy's Adaptation Model was
utilized as the theoretical framework for this study. This chapter will discuss the
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importance of the findings, limitations of the study, implications for nursing, and
recommendations for further research and practice.
Interpretation of the Findings
The sample (yV = 200) included patients >1 8 years of age who received care at one
oi the two rural primary care clinics in north and east central Mississippi and had a
diagnosis ot heart lailure with an ICD-9 diagnosis code of 428. The sample was
primarily compromised o f Caucasians ( n = 159 or 79.5%), with almost equal male (n=
97 oi 48.5 %) and female (n = 103 or 51.5%) participants. The mean age was 75 years
with ages ranging from 35 to 98 years. The primary payer source was Medicare (n = 184
or 92%).
The research project was guided by the following questions:
1. Was the serum potassium level in patients being treated for heart failure
monitored and documented at least every 4 months as recommended by the
Institutes for Clinical Systems Improvement Guidelines for Heart Failure in
Adults?
2. Was the potassium level in the recommended range of 4.0-5.0 mEq/L
according to the 2009 ACCF/AHA recommended guideline when monitored?
3. If the potassium level was not in the recommended range, was there a
medication adjustment?
According to these findings, healthcare providers have a 93.5% compliance rate
with monitoring and documenting the serum potassium level as recommended by the
2009 ACCF/AHA Guidelines for the management of heart failure and the ICSI
Guidelines for Heart Failure in Adults. However, these findings reveal there is a need
among healthcare professionals for continued improvement in this critical area in the
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treatment. Patients with heart failure should be carefully monitored for changes in serum
potassium level. Every effort should be made to prevent the occurrence of either
hypokalemia or hyperkalemia, both of which may adversely affect cardiac excitability
and conduction leading to cardiac arrhythmias and sudden death.
1 he review ot literature indicated the importance of routine monitoring of serum
potassium levels and regulating within the desired range of 4.0-5.0 mEq/L for patients
diagnosed with heart failure. If the acceptable range is not maintained, an alteration of
serum potassium could cause detrimental effects. Age, gender, and ethnicity can be
linked with progression of this deadly disease.
Alper et al. (2009) sought to determine the effects of an alteration of serum
potassium on older adults age 65 years and over diagnosed with heart failure. The
investigators suggested that there were limited studies with this high-risk age group
although the incidence of heart failure increased with age. The data revealed from the
sample of 7,788 participants, 4,036 were 65 years of age or older. Ambulatory adults 65
years of age and older diagnosed with heart failure and hypokalemia had increased
adverse effects and mortality rate. The current research study revealed that 139 of the
200 charts (69.5%) reviewed were 71 years and older. The current study correlates with
the importance of healthcare providers identifying certain high-risk populations,
especially the elderly, in order to decrease the possibilities of an alteration in the serum
potassium level.
Fonarow et al. (2012) identified the significance for following guidelinerecommended therapies in the treatment of heart failure. Without monitoring of serum
potassium levels by healthcare providers in patients prescribed certain medications used
in the treatment of heart failure, serious electrolyte abnormalities can develop. These

abnormalities can lead to cardiac arrhythmias anrl rl(=>Qtn tv
annyinmias and death. The current study correlates the
need tor increased awareness and education in the appropriate treatment of heart failure
patients. Although the data revealed a 93.5% compliance rate following the current
guidelines in regard to monitoring serum potassium levels, it was also shown that
improvement in this area is still needed to improve quality of patient care, reduce
mortality rate, and lessen the economic burden caused by this disease.

Limitations of the Study
Limitations were identified in this study including the fact that data were only
collected from two primary care clinics within the state of Mississippi which may not
adequately represent diversity of the population. Another limitation is the serum
potassium level may have been performed at a specialty office with no results forwarded
to the primary healthcare provider leaving the charts with missing or inaccurate data. In
addition, this study did not identify the reason why a medication adjustment was not done
when the serum potassium level was not within the recommended range of 4.0-5.0
mEq/L. Finally, the various class of medications used to treat heart failure was not
evaluated for their potential effects on serum potassium level.

Implications for Nursing
This study is significant to the nurse practitioner tole because theie aie established
guidelines for managing heart failure which represent evidence-based practices that
healthcare providers are expected to utilize. Sister Callista Roy's Adaptation Model was
used to guide this research study by influencing the relationship between the healthcare
provider and patient. This enhanced relationship encouraged the patient to develop
positive adaptive coping mechanisms leading to a comprehensive, holistic approach to
care.
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Heart failure has an increasing prevalence and high mortality rate which has led to
a growing economic burden to the U.S. at an estimated $40 billion. By performing
routine monitoring of serum potassium level at least every 4 months, an alteration outside
the recommended 4.0-5.0 mEq/L range can be detected and interventions, such as a
medication adjustment, can be implemented to help prevent the development of possible
cardiac complications. 1 hrough this study, nurse practitioners were made aware of the
importance ot adhering to the 2009 ACCF/AHA guidelines for monitoring routine serum
potassium levels in heart failure patients.

Recommendations for Research and Education
Further research can be conducted by replicating this study with an increased
number of clinical sites and a larger sample size to more adequately represent the
population. This would reveal if more healthcare providers are following the 2009
ACCF/AHA guidelines for monitoring routine serum potassium levels in heart failure
patients. A special computer alert for the electronic health record could help ensure that
heart failure patients had a timely evaluation of potassium levels.
The authors believe that provider education is the best way to improve
compliance in monitoring serum potassium levels in heait failuie patients. An
educational in-service, presented to healthcare providers, may increase knowledge and
compliance with the 2009 ACCF/AHA heart failure guidelines. In hopes that healthcare
providers will realize the importance of following recommended guidelines, the authors
plan to present the outcomes of this study to the two rural primary care clinics in which
the data were collected.
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Summary of Implications
Certain medications used in the treatment of heart failure can alter the body's
serum potassium level. A serum potassium level outside the recommended range of 4.05.0 ml.q L in heart iailuie patients can increase adverse cardiac outcomes which can lead
to potentially lile-threatening arrhythmias. The purpose of this study was to determine if
healthcare providers were adhering to the 2009 ACCF/AHA guidelines for monitoring
serum potassium levels in heart failure patients. The study revealed that of the 200 charts
reviewed for the lirst research question 187 patients had documentation of a serum
potassium level within the past 4 months. For the second research question, the authors
determined that 45 out of those 187 patients or 24.1% had a serum potassium level
outside the recommended range of 4.0-5.0 mEq/L. The research findings further
concluded that 25 of the 45 patients who were not within the recommended range or
55.6% received a medication adjustment to help correct the electrolyte imbalance. In
conclusion, healthcare providers were 93.5% compliant with the 2009 ACCF/AFIA
guidelines. If recommendations from this study are applied to practice, heait failuie
patients would receive optimal healthcare decreasing the potential of life-threatening
complications and decreasing outpatient clinic visits and hospitalizations. This could
help improve the quality of life for heart failure patients and reduce the economic burden
of managing heart failure in the U.S.
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APPENDIX A
2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and
Management of Heart Failure in Adults (pp. 1985-1987)
Jessup et al

2009 Guideline Focused Update on Heart Failure

to exclude the presence of primary valve disease. Secondary
changes in valve function, particularly the severity of mitral and
tricuspid valve insufficiency, should be determined.
Noninvasive hemodynamic data acquired at the time of
echocardiography are an important additional correlate for
patients with preserved or reduced EF. Combined quanti
fication of the mitial valve inflow pattern, pulmonary
venous inflow pattern, and mitral annular velocity provides
data about characteristics of LV tilling and left atrial
pressure. Evaluation of the tricuspid valve regurgitant
gradient coupled with measurement of inferior vena caval
dimension and its response during respiration provides an
estimate of systolic pulmonary artery pressure and central
venous pressure. Stroke volume may be determined with
combined dimension measurement and pulsed Dcrpplcr in the
LV outflow tract.21 However, abnormalities can be present in
any of these parameters in the absence of HF. No single
parameter necessarily correlates specifically with HF; however,
a totally normal filling pattern argues against clinical HF.
A comprehensive echocardiography evaluation is important,
because it is common for patients to have more than L cardiac
abnormality thai contributes to the development of HF. Further
more, the study may serve as a baseline for comparison, because
measurement of EF' and the severity of structural remodeling can
provide useful information in patients who have had a change in
clinical status or who have experienced or recovered
from a
clinical event or received
treatment that might have had a
significant effect 011 cardiac function.
Other tests may be used to provide information regarding
the nature and severity of the cardiac abnormality. Radionu
clide ventriculography can provide highly accurate measure
ments of LV function and right ventricular EF, but it is unable
to directly assess valvular abnormalities or cardiac hypertro
phy. Magnetic resonance imaging or computed tomography
may be useful in evaluating chamber size and ventricular
mass, detecting right ventricular dysplasia, or recognizing the
presence of pericardial disease, as well as in assessing cardiac
function and wall motion.25
Magnetic resonance imaging may also be used to identify
myocardial viability and scar tissue.26 Chest radiography can be
used to estimate the degree of cardiac enlargement and pulmo
nary congestion or to detect the presence of pulmonary disease.
A 12-lead electrocardiogram may demonstrate evidence of prior
Ml, LV hypertrophy, cardiac conduction abnonnality (e.g., left
bundle-branch block), or a cardiac arrhythmia. However, be
cause of their low sensitivity and specificity, neither the chest
x-ray nor the electrocardiogram should form Lhe primary basis
for determining the specific cardiac abnoimality responsible for
the development of HF.
3.1.3.2. Laboratory Testing
Laboratory testing may reveal the presence of disorders or
conditions that can lead to or exacerbate HF. The initial
evaluation of patients with HF should include a complete
blood count, urinalysis, scrum electrolytes (including calcium
and magnesium), glycohemoglobin, and blood lipids, as well
as tests of both renal and hepatic function, a chest radiograph,
and a 12-lcad electrocardiogram. Thyroid function tests
(especially thyroid-stimulating hormone) should be meaDownloaded from http://circ ahaj<
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surcd, because both hyperthyroidism and hypothyroidism can
be a primary or contributory cause of HF. A fasting trans
ferrin saturation is useful to screen for hemochromatosis;
several mutated alleles for this disorder are common in
individuals of Northern European descent, and affected pa
tients may show improvement in LV function after treatment
with phlebotomy and chelating agents. Magnetic resonance
imaging of the heart or liver may be needed to confirm the
presence of iron overload. Screening for human immunode
ficiency virus (HIV) is reasonable and should be considered
for all high-risk patients. However, other clinical signs of
HIV infection typically precede any HF symptoms in those
patients who develop HIV cardiomyopathy. Serum titers of
antibodies developed in response to infectious organisms are
occasionally measured in patients with a recent onset of HF
(especially in those with a recent viral syndrome), but the
yield of such testing is low, and Lhe therapeutic implications
of a positive result arc uncertain (sec a recent review of the
role of endomyocardial biopsy,13 and Section 3.1.3.4, Eval
uation of the Possibility of Myocardial Disease, in the
full-text guideline. Assays for connective tissue diseases and
for phcochromocytoma should be performed if these diag
noses are suspected, and serum titers of Chagas disease
antibodies should be checked in patients with nonischemic
cardiomyopathy who have traveled in or emigrated from an
endemic region.
Several recent assays have been developed for natriuretic
peptides (BNP and NT-proBNP). Several of the natriuretic
peptides arc synthesized by and released from the heart.
Elevated plasma BNP levels have been associated with
reduced LVEF,27 LV hypertrophy, elevated LV filling pres
sures, and acute MT and ischemia, although they can occur in
other settings, such as pulmonary embolism and chronic
obstructive pulmonary disease.
Natriuretic peptides tire sensitive to other biological
factors, such as age, sex, weight, and renal function.25
Elevated levels lend support to a diagnosis of abnormal
ventricular function or hemodynamics causing symptom
atic HF.29 Trials with these diagnostic markers suggest use
in the urgcnt-carc setting, where they have been used in
combination with clinical evaluation to differentiate dys
pnea due 10 HF from dyspnea of other causes," and suggest
that its use may reduce both the lime to hospital discharge
and the cost of treatment.30 BNP levels tend to be less
elevated in HF with preserved EF than in HF with low EF
and are lower in obese patients.31 32 Levels of natriuretic
peptides may be elevated meaningfully in women and in
people over 60 years of age who do not have HF, and thus
these levels should be interpreted cautiously in such
individuals when distinguishing between cardiac and noncardiac causes of dyspnea. Elevated natriuretic peptide
levels may lend weight to a suspected diagnosis of HF or
trigger consideration of HF when the diagnosis is unknown
but should not be used in isolation to confirm or exclude
the presence of HF.30-33
3.2.3. Laboratory Assessment
Serum electrolytes and renal function should be monitored
routinely in patients with HF. Of particular importance is the
als.org,'' by guest on June 26, 2013
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serial measurement of serum potassium concentration, be
cause hypokalemia is a common adverse effect of treatment
with diuretics and may cause fatal arrhythmias and increase
the risk of digitalis toxicity, whereas hyperkalemia may
complicate therapy with angiotensin-converting enzyme
(ACEl inhibitors, angiotensin II receptor blockers (ARBs),
and aldosterone antagonists. Worsening renal function may
require adjustment of the doses of diuretics, rcninangiotensin-aldostcronc system antagonists, digoxin, and
noncardiac medications. Development of hyponatremia or
anemia may be a sign of disease progression and is associated
with impaired survival.
Scrum BNP levels have been shown to parallel the clinical
severity of HF as assessed by NYHA class in broad popula
tions. Levels are higher in hospitalized patients and tend to
decrease during aggressive therapy for decompensation (see
Section 3.1.3.2. in the full-text guideline, Laboratory Test
ing).^ Indeed, there is an increasing body of evidence
demonstrating the power of the addition of BNP (or NTproBNP) levels in the assessment of prognosis in a variety of
cardiovascular disorders. However, it cannot be assumed that
BNP levels can be used effectively as targets for adjustment
of therapy in individual patients. Many patients taking opti
mal doses of medications continue to show markedly elevated
levels of BNP, and some patients demonstrate BNP levels
within the normal range despite advanced HF. The use of
BNP measurements to guide the titration of drug doses has
not been shown conclusively to improve outcomes more
effectively than achievement of the target doses of drugs
shown in clinical trials to prolong life.3*' Ongoing trials will
help to determine the role of serial BNP (or other natriuretic
peptides) measurements in both diagnosis and management
of HF.
Serial chest radiographs are not recommended in the
management of chronic HF*. Although the cardiothoracic ratio
is commonly believed to reflect die cardiac dilatation thai is
characteristic of HF, enlargement of the cardiac silhouette
primarily reflects changes in right ventricular volume rather
than LV function, because the right ventricle forms most of
the border of dilated hearts on radiographs. Similarly,
changes in the radiographic assessment of pulmonary vascu
lar congestion arc too insensitive to detect any but the most
extreme changes in fluid status.35
Repeat assessment of EF may be most useful when the
patient has demonstrated a major change in clinical status.
Both improvement and deterioration may have important
implications for future care, although the recommended
medical regimen should be continued in most cases. Improve
ment may reflect recovery' from a previous condition, such as
viral myocarditis or hypothyroidism, or may occur after
titration of recommended therapies for chronic HF*. Thus, it is
appropriate to obtain a repeat EF after some period of optimal
medical therapy, typically 4 to 6 months, to decide about the
implantation of an implantable cardioverter-defibrillator
(ICD) Deterioration may reflect gradual disease progression
or a new event, such as recurrent MI. Routine assessment of
EF at frequent, regular, or arbitrary intervals is not recom
mended.
Downloaded from http://circ.ahaj.

There has been no established role for periodic invasive or
noninvasive hemodynamic measurements in the management
of HF. Most drags used for the treatment of HF are prescribed
on the basis of their ability to improve symptoms or survival
rather than their effect on hemodynamic variables. Moreover,
the initial and target doses of these drugs are selected on the
basis of experience in controlled trials and are not based on
the changes they may produce in cardiac output or pulmonary
wedge pressure. Nevertheless, invasive hemodynamic mea
surements may assist in the determination of volume status
and in distinguishing HF from other disorders that may cause
circulatory instability, such as pulmonary diseases and sepsis.
Measurements of cardiac output and pulmonary wedge pres
sure through a pulmonary artery catheter have also been used
in patients with refractory HF to assess pulmonary vascular
resistance, a determinant of eligibility for heart transplanta
tion. Cardiac output can also be measured by noninvasive
methods.

3.2.4. Assessment of Prognosis
Although both healthcare providers and patients may be
interested in defining the prognosis of an individual patient
with HF, the likelihood of survival can be determined reliably
only in populations and not in individuals. However, some
attempt at prognostication in HF may provide better informa
tion for patients and their families to help them appropriately
plan for their futures. It also identifies patients in whom
cardiac transplantation or mechanical device therapy should
be considered.
Multivariate analysis of clinical variables has helped to
identify the most significant predictors of survival, and prognos
tic models have been developed and validated.36 Decreasing
LVEF, worsening NYHA functional status, degree of hypona
tremia, decreasing peak exercise oxygen uptake, decreasing
hematocrit, widened QRS on 12-lead electrocardiogram, chronic
hypotension, resting tachycardia, renal insufficiency, intolerance
to conventional therapy, and refractory volume overload are all
generally recognized key prognostic parameters, although the
actual prognostic models incorporating them are not widely used
in clinical practice.36-37 Although elevated circulating levels of
neurohormonal factors have also been associated with high
mortality rates, the routine assessment of neurohormones such as
norepinephrine or endothelin is neither feasible nor helpful in
clinical management. Likewise, elevated BNP (or NT-proBNP)
levels predict higher risk of HF and other events after MI.
whereas marked elevation in BNP levels during hospitalization
for HF may predict rehospitalizafion and death. Nonetheless, the
BNP measurement has not been clearly shown to supplement
careful clinical assessment for management
Because treatment of HF has improved over the past 10 years,
the older prognostic models need to be revalidated,33 and newer
prognostic models may have to be developed. Outcomes have
been improved for most high-risk patients, which has resulted in
a shift in the selection process for patients referred for heart
transplantation.33 Routine use of ambulatory electrocardio
graphic monitoring, T-wavc altemans analysts, heart rate vari
ability measurement, and signal-averaged electrocardiography
have not been shown to provide incremental value in assessing
overall prognosis, although ambulatory electrocardiographic
ials.org by guest on June 26, 2013
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monitoring can be useful in decision making regarding place
ment of ICDs.34

4. Therapy
4 3 1•

Patients With Reduced Left Ventricular Ejection
Fraction

Changes m this sectionfocused on 3 areas: recommendations about
electrical device therapy (e.g., cardiac resynchronization therapy
[CRT] and ICDs), the use of a fixed dose combination of
hydralazine and isosorbide dinitrate in self-identified African
Americans, and the management of atrialfibrillation in patients
with IFF. The previous version of the guidelines had a number of
possibly confusing recommendations about selection ofpatients for
ICD implantation. The -writing group has tried to simplify the
recommendations, ami keep them concordant with the most recent
guidelines covering the same issued9^ Updated trial information
has led to the change in the recommemlations about the use of
hydralazineAsosorbide dinitrate and about the management of
atrialfibrillation (Table 3).
4.3.1.1. General Measures
Measures listed as Class I recommendations for patients in
stage A or B are also appropriate for patients with current or
prior symptoms of HF (also see Section 5, Treatment of
Special Populations). In addition, moderate sodium restric
tion, along with daily measurement of weight, is indicated to
permit effective use of lower and safer doses of diuretic drugs,
even if overt sodium retention can be controlled by the use of
diuretics. Immunizarion with influenza and pneumococcal
vaccines may reduce the risk of a respiratory infection.
Although most patients should not participate in heavy labor
or exhaustive sports, physical activity should be encouraged
(except during periods of acute exacerbation of the signs and
symptoms of HF. or in patients with suspected myocarditis),
because restriction of activity promotes physical deconditioning. which may adversely affect clinical status and contribute
to the exercise intolerance of patients with HF.,4a-,4S
Three classes of drugs can exacerbate the syndrome of HF
and should be avoided in most patients:
1. Antiarrhythmic agents'4* can exert important cardiodcpressant and proarrhythmic effects. Of available agents,
only amiodaronc and dofetilide147 have been shown not to
adversely affect survival.
2. Calcium channel blockers can lead to worsening HF and
have been associated with an increased risk of cardiovas
cular events.148 Of available calcium channel blockers,
only the vasoselective ones have been shown not to
adversely affect survival.'34'144
3 Nonsteroidal anti-inflammatory dings can cause sodium
retention and peripheral vasoconstriction and can attenuate
the efficacy and enhance the toxicity of diuretics and ACE
inhibitors.84-87 A discussion of the use of aspirin as a
unique agent is found later in this section (sec Section
4.3 1.2.2.1., Angiotensin Converting Enzyme Inhibitors
in the Management of Heart Failure, in the full-text
guideline).
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Patients with HF should be monitored carefully for
changes in serum potassium, and every effort should be made
to prevent the occurrence of either hypokalemia or hyperka
lemia, both of which may adversely affect cardiac excitability
and conduction and may lead to sudden death.'50 Activation
of both the sympathetic nervous system and renin-angiotensin
system can lead to hypokalemia,'51-152 and most drugs used
for the treatment of HF can alter serum potassium.153 Even
modest decreases in scrum potassium can increase the risks of
using digitalis and antiarrhythmic drugs,'50-154 and even
modest increases in serum potassium may prevent the use of
treatments known to prolong life.'55 Hence, many experts
believe that scrum potassium concentrations should be tar
geted in the 4.0 to 5.0 mmol per liter range. In some patients,
correction of potassium deficits may require supplementation
of magnesium and potassium.156 In others (particularly those
taking ACH inhibitors alone or in combination with aldoste
rone antagonists), the routine prescription of potassium salLs may
be unnecessary and potentially deleterious.
Of the general measures that should be used in patients
with HF, possibly the most effective yet least used is close
observation and follow-up. Nonadherents with diet and
medications can rapidly and profoundly affect the clinical
status of patients, and increases in body weight and minor
changes in symptoms commonly precede by several days the
occurrence of major clinical episodes that require emergency
care or hospitalization. Patient education and close supervi
sion, which includes surveillance by the patient and his or her
family, can reduce the likelihood of nonadherence and lead to
the detection of changes in body weight or clinical status
early enough to allow the patient or a healthcare provider an
opportunity to institute treatments that can prevent clinical
deterioration. Supervision need not be performed by a phy
sician and may ideally be accomplished by a nurse or
physician's assistant with special training in the carc of
patients with HF. Such an approach has been reported to have
significant clinical benefits.157-160
Recommendations Concerning Aldosterone Antagonists. The
addition of low-dose aldosterone antagonists is recommended
in carefully selected patients with moderately severe or
severe HF symptoms and recent decompensation or with LV
dysfunction early after Mr. These recommendations are based
on the strong data demonstrating reduced death and rehospitaliz.ation in 2 clinical trial populations.'55-'6' The entry
criteria for these trials describe a broader population than was
actually enrolled, such that the favorable efficacy/ toxicity
ratio may not be as applicable to patients at the margins of
trial eligibility. For both of these major trials, patients were
excluded for a serum creatinine level in excess of 2.5 mg per
dL, but few patients were actually enrolled with serum
creatinine levels over 1.5 mg per dL. In the trial of patients
after MI. there was a significant interaction between scrum
creatinine and benefit of cplcrenonc. The average serum
creatinine of enrolled patients was 1.1 mg per cIL, above
which there was no demonstrable benefit for survival.
To minimize the risk of lifc-thrcatcning hyperkalemia in
patients with low LVEF and symptoms of HF, patients should
have initial serum creatinine less than 2.0 to 2.5 mg per dL
without recent worsening and serum potassium less than 5.0
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APPENDIX B
Institute lor Clinical Systems Improvement: Health Care Guidelines for
Heart Failure in Adults 2011 (p. 15)
using either continuous infusion or bolus intravenous injections [Meta-Analysis],
In acute decompensated heart failure, there also has been shown to be no
difference in the use of low dose (equivalent to the patient's previous oral dose)
or high dose (2.5 times the previous oral dose) in terms of the patient's global
assessment of symptoms or in the change in renal function. Therefore, no
benefit is seen to either low versus high dose or infusion versus bolus injection
as long as adequate natriuresis is maintained.

• Sodium, Potassium, Chloride/Bicarbonate, BUN/Scr (basic chemistry
panel)
•

Before diuretic initiation

•

During the diuretic initiation phase, the first lab after starting therapy is
dependent on the degree of diuresis:
•

Outpatients on oral diuretic therapy should have their labs
repeated once approximately five to seven days after diuretic
initiation. If lab abnormalities are present, labs should be
repeated weekly until they have stabilized.

•

Inpatients on large intravenous (IV) doses of diuretics
(including drips) or who require frequent dose changes should
have labs repeated daily at a minimum.

•

Following the initiation phase, stable outpatient diuretic patients should
have a basic chemistry panel drawn every four months for the duration
of therapy. If any of the following occurs, lab monitoring will need to be
more frequent until the patient stabilizes:
•

Changes in diuretic dose, route, or frequency

•

The patient's condition worsens

•

The patient develops signs/symptoms of electrolyte
abnormalities

•

If lab abnormalities are found at any time, increased lab surveillance is
warranted until levels have normalized.

• Magnesium, Calcium

.

Before diuretic initiation, then every four months for the duration of
therapy

• Glucose Checks (diabetic patients)

•

Before diuretic initiation
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APPENDIX C
Approval of Mississippi University for Women's
Institutional Review Board

Mississippi University
for Women
A Tradition of Excellence for Women and Men

Provost and Vice President for Academic Affairs
1100 College St. MUW-1603
Columbus, MS 39701-5800
(662) 329-7142
(662) 329-7141 Fax
www.muw.eiiu

May 31,2013

Sueanne Davidson, DNP
Mississippi University for Women
College of Nursing and Speech-Language Pathology
MUW - 910
Columbus, Mississippi 39701-5800
Dear Dr. Davidson:
I am pleased to inform you that the members of the Institutional Review Board (IRB)
have reviewed the following revised proposed research and have approved it as
submitted:
Name of Study:

Health Care Provider's Monitoring of
Potassium Levels in the Treatment of Heart
Failure

Investigator(s):

Lori Duke and Cindy Patrick

Research
Faculty/Advisor:

Sueanne Davidson

I wish you much success in your research.
Sincerely,

-7>i
Dan Heimmermann, Ph.D.
Provost and Vice President for Academic Affairs
DH/jh
pc: Tammie McCoy, Institutional Review Board Chairman
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APPENDIX D
Letter ot Consent for Participation in a Research Study
January 28, 2013
Dear Healthcare Provider,
\\ e are graduate students in the Family Nurse Practitioner Program at Mississippi
I niveisity for Women in Columbus, MS. As a program requirement for graduation, we
aie conducting a quality assurance research study to assess compliance of
recommendations for monitoring potassium from the American College of Cardiology
Foundation/American Heart Association (ACCF/AHA) and the Institute for Clinical
Systems Improvement guidelines for heart failure in adults. Potassium is one of our
body s main intracellular electrolytes, which could cause an adverse cardiac event if the
level is not monitored and kept in the acceptable range for this diagnosis. The results of
this study will improve the healthcare provider's adherence to the 2009 ACCFAHA
guidelines in the care ot heart failure patients, enhancing patient outcomes and decreasing
the potential of life-threatening complications.
We would like to use your facility's charts for compiling data for this study. Your
participation will involve granting us the privilege of reviewing 100 medical records of
your patients 18 years of age and older with ICD-9 diagnosis code 428 for heart failure.
We agree to refrain from discussing or disclosing any information regarding your clients.
All information acquired from this retrospective chart review would be completely
confidential. Neither names of patients nor the facility name will be used in the study.
Each researcher will receive HIPAA and Corporate Compliance training through the
facility before beginning the research. The chart reviews will be recorded on a data
collection worksheet. The information will be entered into a computer data sheet for
preparation of statistical analysis and saved to a password-protected media drive. The
media drive and worksheets will be destroyed at the end of the study. The facility may
withdraw at any time and participation is voluntary. Results of this research study will
be shared with each facility and provider. Specific providers will not be named, and data
will be resulted as a group.
If you would like any further information, please feel free to contact Lori Duke at (662)
882-0798 or lduke2009@yahoo.com, Cindy Patrick (601) 513-2337 or
Cpatrickmuw2012 @gmail.com, or contact the chair of our research committee, Dr.
Sueanne Davidson, at (662) 329-7322 or Sdavidson@nsgslp.muw.edu. Thank you for
your willingness to consider this request.

Sincerely,
Lori Duke, RN, BSN
Cindy Patrick, RN, BSN, CCRN
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APPENDIX E
Data Collection Worksheet
Date of chart review
1. Patient's gender: Male
2. Patient's age

(1)

Female

(2)

years

3. Ethnicity:
Caucasian

(1)

Other

African-American

(2) Hispanic

(3)

(4)

4. Was a serum potassium level checked in the last four months?
Yes

(1) No

(2)

5. Was the last serum potassium level between 4.0-5.0 mEq/L?
Yes

(1) No

(2)

6. Was a medication adjustment made if the serum potassium level was not in the 4.05.0 mEq/L range?
Yes

(1) No

(2)

7. Is this patient on any of the following medications?
ARB

(1)

ACE-I

Beta-blockers

(2)

Aldosterone Antagonist

(3)

(4) Diuretic (loop, thiazide, or potassium-sparing)

8. What was the payer source?
Medicare
Self-pay

(1) Medicaid
(4)

(2) commercial

(3)

(5)

